Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGAV | P06756 | 20/20 | 0.68 |
| ▸ | ITGB3 | P05106 | 17/20 | 0.68 |
| ▸ | ITGB6 | P18564 | 15/20 | 0.68 |
| ▸ | ITGA2B | P08514 | 7/20 | 0.68 |
| ▸ | ITGB5 | P18084 | 7/20 | 0.62 |
| ▸ | ITGB8 | P26012 | 4/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2841497 | 0.87 | ITGAV (0.74) | ITGAVITGB3ITGB6ITGA2BITGB5 | |
| SCHEMBL2837431 | 0.87 | ITGAV (0.75) | ITGAVITGB3ITGB6ITGA2BITGB5 | |
| SCHEMBL1825834 | 0.86 | ITGB3 (0.83) | ITGAVITGB3ITGB6ITGA2BITGB5 | |
| SCHEMBL1825833 | 0.86 | ITGB3 (0.83) | ITGAVITGB3ITGB6ITGA2BITGB5 | |
| SCHEMBL2841970 | 0.84 | ITGB3 (0.75) | ITGAVITGB3ITGB6ITGA2BITGB5 | |
| SCHEMBL5848255 | 0.81 | ITGAV (1.00) | ITGAVITGB3ITGB6ITGA2BITGB5 | |
| SCHEMBL7678539 | 0.81 | ITGB3 (0.75) | ITGAVITGB3ITGB6ITGA2BITGB5 | |
| Hydrochloric Acid SCHEMBL5848111 | 0.80 | ITGAV (0.98) | ITGAVITGB3ITGB6ITGA2BITGB5 | |
| SCHEMBL2838998 | 0.80 | ITGAV (0.78) | ITGAVITGB3ITGB6ITGA2BITGB5 | |
| SCHEMBL6421854 | 0.80 | ITGAV (1.00) | ITGAVITGB3ITGB6ITGA2BITGB5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210284638-A1 | ALPHAvBETA1 INTEGRIN ANTAGONISTS | SAINT LOUIS UNIVERSITY (US) | 2021-09-16 | — | — | US | disclosed |
| US-20190345155-A1 | INTEGRIN ANTAGONISTS | Indalo Therapeutics, Inc. | 2019-11-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210284638-A1 | ALPHAvBETA1 INTEGRIN ANTAGONISTS | ITGB1, ITGAV, ITGA1 | ITGAV 2/4885ITGB3 12/4885ITGB6 13/4885 |
| US-20190345155-A1 | INTEGRIN ANTAGONISTS | ITGA5, ITGB5, ITGB2 | ITGAV 10/4885ITGB3 11/4885ITGB6 12/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.